Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab

Summary

This is a single arm, open-label, Phase 1b study of pembrolizumab for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) whose disease has relapsed after receiving allogeneic hematopoetic stem cell transplant.

Timeline

Start

2017-12-21

Primary completion

2020-10-22

Completion

2021-04-28

Outcome

Outcome not reported

Stopped: “Lack of patient population”

Publications

• Magenau JM, Frame DG, Riwes M, Maciejewski J, Anand S, Pawarode A, Perry AM, Geer M, Braun T, Ghosh M, Reddy P. PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2025 Aug 12;9(15):3878-3886. doi: 10.1182/bloodadvances.2024015200.

Drugs

Indications